View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 2, 2021updated 02 Nov 2021 6:57am

Boston Scientific acquires surgical business of Lumenis for $1.07bn

BPEA will continue to hold the rights to Lumenis’ international aesthetics and ophthalmology businesses.  

Boston Scientific has concluded the acquisition of the international surgical business of Lumenis from a Baring Private Equity Asia (BPEA) affiliate following an upfront payment of $1.07bn.

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

In March, Boston Scientific signed a definitive agreement to acquire the surgical business.

Lumenis creates and markets energy-based medical solutions for less-invasive aesthetic and vision applications.

The Lumenis surgical business comprises laser systems, fibres, and accessories utilised in urology and otolaryngology procedures and has predicted total revenue of nearly $200m for full-year 2021.

With the acquisition, Lumenis intends to focus on and expedite scheduled investments to back the development of its quickly expanding aesthetic and vision businesses.

Furthermore, the company will focus on research and development (R&D), international sales, and marketing channels and business development works.

Boston Scientific will market the lasers and fibres as well as the otolaryngology laser portfolio to all regions, including increased growth regions such as China.

Boston Scientific and Lumenis have been collaborating for more than two decades.

Previously, Boston Scientific supplied the urology laser portfolio of Lumenis in the US and Japan under a supply arrangement.

The ownership of Lumenis’ global aesthetics and ophthalmology businesses will be retained by BPEA, the company noted.

Boston Scientific urology and pelvic health senior vice-president and president Meghan Scanlon said: “The close of this acquisition allows us to integrate the Lumenis laser portfolio – including the differentiated MOSES technology – with our category-leading kidney stone management and benign prostatic hyperplasia offerings while expanding our global footprint to accelerate growth throughout Europe and Asia.

“Additionally, we are welcoming significant talent to our urology and pelvic health team, and we are excited to establish our global surgical laser centre of excellence in Yokneam where we will continue our focus on advancing innovation to help surgeons improve patient care.”

Last month, the US Food and Drug Administration granted 510(k) clearance to Boston Scientific’s EXALT Model B Single-Use Bronchoscope for use in bedside procedures in intensive care units and operating rooms.

Related Companies

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network